AFTX-201, Affinia’s gene therapy program in BAG3 dilated cardiomyopathy, demonstrates efficacy, safety, and differentiation in a genetically relevant preclinical model, with full restoration of cardiac function Additional data show Affinia’s gene therapy program in MYBPC3 hypertrophic…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.